Seasoned health care and technology executive who has built multiple companies from start up to over $100 million in revenue. Success in both the start-up and Fortune 50 settings. Experienced in building technical, scientific, service, sales, and clinical organizations. Raised over $200 million in venture capital investment over multiple companies in various industries.As Co-founder, President, and CEO of Ocugenix, we created a new chemical entity (NCE) based on a deep knowledge of the molecular mechanism of wound healing. We developed it to treat the number one cause of blindness, wet macular degeneration. Guided the program from initial chemical discovery through the establishment of efficacy, establishment of safety, manufacturing, and formulation. In the summer of 2023, we received an IND from the FDA, enabling us to start our first-in-human program. In the spring of 2024, we completed our Phase I study and are preparing to launch the Phase II program in the next several months.Chairman of Aethon, an autonomous robotics company that automated deliveries and the supply chain in hospitals, warehouses, and manufacturing facilities. Acquired by ST Engineering of Singapore. President and CEO built Precision Therapeutics into a market-leading personalized medicine company through internal development and executing an aggressive acquisition strategy. Drove overall business strategy, including product development, clinical validation, and market development. Achieved proprietary reimbursement for products, realizing gross margins of over 85%. Developed the most diversified portfolio in the industry of validated personalized medicine products impacting lung, colon, and gynecological cancers.As Group President of McKesson, I oversaw six separate operating divisions delivering technology solutions in diverse areas such as robotics, ERP, and e-commerce. Turned around a shrinking technology division to a 30% annual growth rate in the first year after assuming control.Founder of Automated Healthcare, a robotics based automation system that transformed the pharmacy segment. Later sold company to McKesson realizing over 600% ROI for investors.Specialties: Technology management, sales, finance, product development, raising capital, managing growth